Literature DB >> 10891264

Structures of type 2 peroxisomal targeting signals in two trypanosomatid aldolases.

D M Chudzik1, P A Michels, S de Walque, W G Hol.   

Abstract

Trypanosomatids, unicellular organisms responsible for several global diseases, contain unique organelles called glycosomes in which the first seven glycolytic enzymes are sequestered. We report the crystal structures of glycosomal fructose-1,6-bisphosphate aldolase from two major tropical pathogens, Trypanosoma brucei and Leishmania mexicana, the causative agents of African sleeping sickness and one form of leishmaniasis, respectively. Unlike mammalian aldolases, the T. brucei and L. mexicana aldolases contain nonameric N-terminal type 2 peroxisomal targeting signals (PTS2s) to direct their import into the glycosome. In both tetrameric trypanosomatid aldolases, the PTS2s from two different subunits form two closely intertwined structures. These "PTS2 dimers", which have very similar conformations in the two aldolase structures, are the first reported conformations of a glycosomal or peroxisomal PTS2, and provide opportunities for the design of trypanocidal compounds. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891264     DOI: 10.1006/jmbi.2000.3910

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  20 in total

1.  Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate.

Authors:  Aurora Ortiz-Gómez; Carmen Jiménez; Antonio M Estévez; Juana Carrero-Lérida; Luis M Ruiz-Pérez; Dolores González-Pacanowska
Journal:  Eukaryot Cell       Date:  2006-07

2.  Glycerol 3-phosphate alters Trypanosoma brucei hexokinase activity in response to environmental change.

Authors:  Heidi C Dodson; Meredith T Morris; James C Morris
Journal:  J Biol Chem       Date:  2011-08-03       Impact factor: 5.157

Review 3.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

4.  Empirical power laws for the radii of gyration of protein oligomers.

Authors:  John J Tanner
Journal:  Acta Crystallogr D Struct Biol       Date:  2016-09-15       Impact factor: 7.652

5.  Structure of a class I tagatose-1,6-bisphosphate aldolase: investigation into an apparent loss of stereospecificity.

Authors:  Clotilde LowKam; Brigitte Liotard; Jurgen Sygusch
Journal:  J Biol Chem       Date:  2010-04-28       Impact factor: 5.157

6.  Mannitol Bis-phosphate Based Inhibitors of Fructose 1,6-Bisphosphate Aldolases.

Authors:  Charles-Gabin Mabiala-Bassiloua; Guillaume Arthus-Cartier; Véronique Hannaert; Hélène Thérisod; Jurgen Sygusch; Michel Thérisod
Journal:  ACS Med Chem Lett       Date:  2011-09-03       Impact factor: 4.345

Review 7.  State of the art in African trypanosome drug discovery.

Authors:  Robert T Jacobs; Bakela Nare; Margaret A Phillips
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

8.  The krebs cycle enzyme α-ketoglutarate decarboxylase is an essential glycosomal protein in bloodstream African trypanosomes.

Authors:  Steven Sykes; Anthony Szempruch; Stephen Hajduk
Journal:  Eukaryot Cell       Date:  2014-11-21

9.  Homology modeling and molecular dynamics study of NAD-dependent glycerol-3-phosphate dehydrogenase from Trypanosoma brucei rhodesiense, a potential target enzyme for anti-sleeping sickness drug development.

Authors:  Igor Z Zubrzycki
Journal:  Biophys J       Date:  2002-06       Impact factor: 4.033

10.  Functional similarity between the peroxisomal PTS2 receptor binding protein Pex18p and the N-terminal half of the PTS1 receptor Pex5p.

Authors:  Antje Schäfer; Daniela Kerssen; Marten Veenhuis; Wolf-H Kunau; Wolfgang Schliebs
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.